Comparative Pharmacology
Head-to-head clinical analysis: FLAC versus GIAZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAC versus GIAZO.
FLAC vs GIAZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAC (Fluorouracil) is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. It is converted to active metabolites (FdUMP, FUTP) that disrupt RNA function and DNA replication.
Balsalazide is a prodrug that is converted by colonic bacteria into mesalamine (5-aminosalicylic acid), which inhibits prostaglandin and leukotriene production, reducing colonic inflammation.
Adults: 40 mg orally twice daily.
Adults: 2 tablets (1.2 g) orally three times daily (3.6 g/day) for up to 6 weeks.
None Documented
None Documented
2-4 hours; prolonged in renal impairment (up to 12 hours)
Terminal elimination half-life approximately 0.5-1.0 hour for 5-ASA (active); metabolite half-life ~5-10 hours. Clinical context: short half-life necessitates multi-matrix release formulation for once-daily dosing in ulcerative colitis.
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%
Primarily metabolized in the gut mucosa and liver to N-acetyl-5-aminosalicylic acid. Renal excretion of acetylated metabolite accounts for ~25-30% of dose; fecal excretion of parent drug and metabolite ~50-60%. Biliary excretion minimal.
Category C
Category C
Corticosteroid
Corticosteroid